ChartRow logo
Data provided bySource: Twelve Data
BMRN
$58.51+0.90%
as of close, Nov 17, 2026
☾ AH $58.51 +0.90%
Share this page

BMRN financial statements

The full income statement, balance sheet, and cash-flow statement for BioMarin Pharmaceutical Inc. (BMRN), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Financial overview#

Revenue

5Y CAGR +11.6%10Y CAGR +13.7%YoY +32.0%
$3.7B TTM$1B Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Gross profit

5Y CAGR +13.4%10Y CAGR +13.0%YoY +28.9%
$2.5B FY25— Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m10Y n/mYoY n/m
$113.9M TTM−$82.1M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR −16.4%10Y n/mYoY n/m
−$19.1M TTM−$122.8M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR −16.7%10Y n/mYoY n/m
−$0.10 TTM−$0.63 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating cash flow

5Y CAGR +57.5%10Y n/mYoY −48.9%
$676.6M TTM$188.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Capital expenditure

5Y CAGR −2.1%10Y CAGR −7.6%YoY −0.5%
$118.8M TTM$28.3M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m10Y n/mYoY −53.0%
$557.9M TTM$159.9M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Shares (diluted)

5Y +3.0%10Y +23.4%YoY +0.8%
196.2M TTM193.6M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Every BMRN chart on Trends →

Shares outstanding (point-in-time)

2024-09 190.6M2024-12 190.8M2025-03 191.8M2025-06 192.0M2025-09 192.1M2025-12 192.3M2026-03 193.3M2026-06 193.6M2026-09 193.7M+1.6% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeFiguresAs-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Revenue3.22B+12.9%2.85B+18.0%2.42B+15.4%2.10B+13.5%1.85B-0.8%
2.50B+10.1%2.27B+20.5%1.89B+18.5%1.59B+15.8%1.38B+3.0%
Cost of revenue717M+23.6%580M+9.1%532M+5.8%503M+6.9%471M-10.3%
Research & development922M+23.4%747M+0.1%747M+15.0%650M+3.3%629M+0.1%
Selling, general & administrative1.15B+14.3%1.01B+13.1%892M+8.4%823M+8.4%759M+2.9%
Amortization of intangibles19.4M-55.2%43.3M-30.5%62.2M-7.4%67.2M—
Operating income409M-15.4%484M+160.6%186M+15.4%161M+295.5%-82.3M-89.6%
Interest expense10.9M-14.0%12.7M-26.9%17.3M+8.5%16.0M+4.1%15.3M-47.7%
Interest & investment income74.9M+0.0%74.9M+28.4%58.3M+223.5%18.0M+72.0%10.5M-36.9%
Pre-tax income482M-10.9%542M+187.3%189M+26.1%150M+298.5%-75.3M-53.8%
Income tax134M+16.3%115M+449.3%20.9M+161.0%8.02M+171.1%-11.3M+98.8%
349M-18.3%427M+154.6%168M+18.4%142M+320.9%-64.1M-107.5%
Net income to common349M-18.3%427M+154.6%168M+18.4%142M+320.9%-64.1M-107.5%
$1.80-18.6%$2.21+154.0%$0.87+16.0%$0.75+314.3%-$0.35-107.8%
EPS (basic)$1.82-19.1%$2.25+152.8%$0.89+17.1%$0.76+317.1%-$0.35-107.4%
Weighted-avg shares (basic)192M+0.9%190M+1.2%188M+1.4%185M+1.3%183M+1.1%
Weighted-avg shares (diluted)197M+0.3%197M+2.7%192M+1.4%189M+3.3%183M-4.6%
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
3.95B+22.3%3.23B+9.3%2.96B+7.4%2.75B+21.0%2.27B-2.9%
Cash & equivalents1.31B+39.1%943M+24.9%755M+4.2%725M+23.4%587M-9.5%
Accounts receivable908M+37.5%661M+4.2%634M+37.4%461M+23.5%373M-16.7%
Inventory1.30B+5.4%1.23B+11.3%1.11B+23.8%894M+15.1%777M+11.2%
Other current assets186M-7.8%202M+42.5%141M+35.3%105M-5.4%110M-15.0%
7.59B+8.7%6.99B+2.2%6.84B+7.3%6.38B+6.2%6.00B+2.7%
Property, plant & equipment953M-8.7%1.04B-2.2%1.07B-0.7%1.07B+3.7%1.04B+0.3%
Operating lease right-of-use35.2M+22.9%28.7M-32.9%42.7M+22.3%34.9M-8.5%38.2M-17.0%
Goodwill196M+0.0%196M+0.0%196M+0.0%196M+0.0%196M+0.0%
Intangible assets214M-16.2%255M-13.4%295M-13.0%339M-12.9%389M-6.9%
Deferred tax assets1.51B+1.3%1.49B-3.7%1.55B+2.7%1.51B+3.8%1.45B+1.3%
Other non-current assets277M+10.2%251M+46.6%172M-2.7%176M+15.9%152M+6.9%
759M+25.0%607M-48.4%1.18B+99.9%589M+7.8%546M+11.0%
Accounts payable
30.7M————
Accrued liabilities759M+25.0%607M-11.1%683M+19.2%573M+15.0%498M+1.2%
Deferred revenue—1.37M-70.4%4.62M+549.8%711K-89.8%6.96M+4476.3%
Short-term & current debt0.000.00-100.0%494M0.00—
Current lease liability8.57M+18.5%7.23M-16.3%8.64M+6.8%8.09M-1.3%8.20M-7.8%
Finance lease liability (current)116K-66.0%341K+145.3%139K-93.9%2.29M+0.9%2.27M-20.9%
1.51B+13.2%1.33B-29.6%1.89B+6.7%1.77B+1.9%1.74B-0.2%
Long-term debt597M+0.3%595M+0.3%593M-45.2%1.08B+0.4%1.08B+0.4%
Non-current lease liability36.6M+19.9%30.5M-19.8%38.0M+44.5%26.3M-17.4%31.9M-21.2%
Operating lease liability (total)45.1M+19.6%37.7M-19.2%46.7M+35.7%34.4M-14.1%40.1M-18.8%
Finance lease liability (total)552K-49.7%1.10M+407.9%216K-91.3%2.47M-41.5%4.23M-38.5%
Finance lease liability436K-42.3%756K+881.8%77.0K-58.2%184K-90.6%1.96M-51.1%
Other non-current liabilities151M+17.1%129M+7.4%120M+19.9%100M+1.7%98.4M-13.9%
6.09B+7.6%5.66B+14.3%4.95B+7.6%4.60B+7.9%4.27B+3.9%
Common stock192K+0.5%191K+1.1%189K+1.6%186K+1.1%184K+1.1%
Additional paid-in capital5.96B+2.7%5.80B+3.4%5.61B+3.8%5.40B+4.1%5.19B+4.0%
Retained earnings154M+179.2%-195M+68.7%-622M+21.2%-789M+15.2%-931M-8.0%
Accumulated other comprehensive income-13.5M-121.9%61.7M+314.2%-28.8M-644.5%-3.87M-126.8%14.4M+189.4%
Total equity incl. non-controlling6.09B+7.6%5.66B+14.3%4.95B+7.6%4.60B+7.9%4.27B+3.9%
Total liabilities & equity7.59B+8.7%6.99B+2.2%6.84B+7.3%6.38B+6.2%6.00B+2.7%
Common shares issued192M+0.8%191M+1.1%189M+1.3%186M+1.3%184M+1.2%
Common shares outstanding192M+0.8%191M+1.1%189M+1.3%186M+1.3%184M+1.2%
Shares outstanding (cover)192M+0.8%191M+1.1%189M+1.2%187M+1.4%184M+1.2%
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
828M+44.5%573M+259.7%159M-9.5%176M-42.2%305M+256.7%
Depreciation & amortization79.6M-17.5%96.4M-7.6%104M+2.4%102M-5.6%108M+2.7%
Intangible amortization19.4M-55.2%43.3M-30.5%62.2M-7.4%67.2M—
Share-based compensation181M-10.0%202M-2.7%207M+5.5%196M-0.5%197M+4.0%
Deferred income taxes48.7M-13.1%56.1M+224.7%-45.0M+13.6%-52.1M-233.7%-15.6M+98.2%
Change in receivables228M+293.8%57.9M-69.6%190M+132.1%82.0M+225.1%-65.6M-211.1%
Change in inventory117M+84.1%63.5M-59.5%157M+130.1%68.3M+94.7%35.1M-42.7%
-414M-403.5%136M+222.7%-111M-455.4%-20.0M+94.5%-366M-583.2%
Capital expenditure103M+20.6%85.4M-11.7%96.7M-20.1%121M+26.6%95.6M-16.4%
Free cash flow725M+48.7%487M+679.0%62.6M+13.9%54.9M-73.7%209M+821.9%
Acquisitions—0.000.000.000.00
Purchases of investments356M-13.3%410M-52.8%868M+42.0%612M-34.7%937M+76.9%
Sales/maturities of investments338M-46.6%633M-26.8%865M+39.5%620M-10.3%691M+24.3%
Other investing activities0.00+100.0%-1.14M0.000.00-100.0%994K+37.5%
-42.4M+91.9%-526M-2711.2%-18.7M-0.4%-18.6M-38754.2%-48.0K-100.0%
Long-term debt issued0.000.000.000.000.00
Long-term debt repaid0.000.000.000.000.00
Common stock issued0.000.000.000.000.00
Common stock repurchased0.000.000.000.000.00-100.0%
Dividends paid0.000.000.000.000.00
Other financing activities-889K+72.0%-3.18M+73.0%-11.8M-351.5%-2.60M-554.5%-398K
FX effect on cash
————-57.0K+95.0%
Net change in cash369M+96.5%188M+513.5%30.6M-77.7%137M+321.8%-61.9M-129.2%
Interest paid7.25M-30.1%10.4M+0.6%10.3M+0.2%10.3M-1.1%10.4M-14.6%
Income taxes paid96.2M+68.0%57.3M-21.9%73.3M+34.8%54.4M+199.5%18.2M+102.2%
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Market cap11.4B-8.9%12.5B-31.0%18.2B-5.6%19.2B+18.4%16.2B+2.0%
P/E32.8×+11.5%29.4×-76.2%123.5×-46.1%229.2×—
P/S3.5×-19.2%4.4×-44.1%7.9×-17.9%9.6×+8.8%8.8×+2.7%
P/B1.9×-15.3%2.2×-40.2%3.7×-11.9%4.2×+10.5%3.8×-1.9%
P/FCF15.8×-38.7%25.7×-95.0%517.4×+78.3%290.2×+273.1%77.8×
Earnings yield3.1%-10.3%3.4%+320.6%0.81%+85.5%0.44%—
FCF yield6.3%+63.2%3.9%+1911.5%0.19%-43.9%0.34%-73.2%1.3%
Source filing10-K10-K10-K10-K10-K
Fiscal yearCEOTotal, as reportedActually paidOther executives, average$100 in the stock$100 in peers
FY2025Alexander Hardy$21.9M$12.2M$6.4M$67.77$124.75
FY2024Alexander Hardy$14.9M$2.4M$6.6M$74.96$93.49
FY2023Jean-Jacques Bienaime $22M / $15.8MAlexander Hardy $17.9M / $18.5M$39.9M$34.3M$6.3M$109.96$94.03
FY2022Jean-Jacques Bienaime$18.4M$34.4M$6.1M$118.02$89.90
FY2021Jean-Jacques Bienaime$18.3M$18.4M$5.5M$100.75$100.02
FY2020Jean-Jacques Bienaime$18.1M$22.3M$5.2M——

From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.

About this data

Source: BMRN’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all BMRN filings on SEC EDGAR → Not investment advice.